An Evidence-Based Approach to the Management of Depression

Primary Care - Clinics in Office Practice

Volumn 33, Issue 4, 2006, Pages 923-941

  Maurer, Douglas ^a   Colt, Ross ^a  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENYTOIN; PRASTERONE; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ACUPUNCTURE; ADOLESCENT DISEASE; ALTERNATIVE MEDICINE; AUTOMUTILATION; BEHAVIOR THERAPY; BIRTH RATE; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED PRACTICE; EXERCISE; FATIGUE; FETOTOXICITY; FETUS MALFORMATION; HEADACHE; HEALTH CARE MANAGEMENT; HEALTH PROGRAM; HEART INFARCTION; HEART PALPITATION; HERBAL MEDICINE; HOSTILITY; HUMAN; HYPERICUM PERFORATUM; HYPOMANIA; KINESIOTHERAPY; MAINTENANCE THERAPY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT COUNSELING; PATIENT EDUCATION; PHOTOTHERAPY; PHYSICIAN; PRACTICE GUIDELINE; PREGNANCY; PREMATURE LABOR; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SCREENING TEST; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SPONTANEOUS ABORTION; STROKE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SUPPLEMENTATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT PLANNING; TREMOR; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; CHILD; COMPLEMENTARY THERAPIES; COUNSELING; DEPRESSIVE DISORDER; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE;

EID: 33845309133     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2006.09.003     Document Type: Review

References (96)

1. The world health report 2002-reducing risks, promoting healthy life (2002), World Health Organization, Geneva
2. Narrow W.E., Rae D.S., Robins L.N., et al. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 survey's estimates. Arch Gen Psychiatry 59 (2002) 115-123
3. Coyne J.C., Fechner-Bates S., and Schwenk T.L. Prevalence, nature, and comorbidity of depressive disorders in primary care. Gen Hosp Psychiatry 51 (1994) 8-19
4. Chisholm D. The economic costs of depression. In: Dawson A., and Tylee A. (Eds). Depression: social and economic timebomb (2001), BMJ Books, London 10-12
5. Goldman L.S., Nielsen N.H., and Champion H.C. Awareness, diagnosis, and treatment of depression. J Gen Intern Med 14 (1999) 569-580
6. Mueller T.L., Leon A.C., Keller M.B., et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 156 (1999) 1000-1006
7. Keller M.B., Lavori P.W., Rice J., et al. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry 143 (1986) 24-28
8. Ford D.E. Depression is a risk factor for coronary artery disease in men. The precursors study. Arch Intern Med 158 (1998) 1422-1426
9. Ciechanowski P.S., Kanton W.J., and Russo J.E. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 160 (2000) 3278-3285
10. Robinson R.G., Bolduc P., and Price T.R. Two-year longitudinal study of poststroke mood disorders: diagnosis and outcome at one and two year follow-up. Stroke 18 (1987) 837-843
11. Taylor C.B., Youngblood M.E., Catellier D., et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after acute myocardial infarction. Arch Gen Psychiatry 62 (2005) 792-798
12. Jorge R.E., Robinson R.G., Arndt S., et al. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry 160 (2003) 1823-1829
13. Gibbons R.D., Hur K., Bhaumik D.K., et al. The relationship between antidepressant use and rate of suicide. Arch Gen Psychiatry 62 (2005) 165-172
14. Cornwall P.L., and Scott J. Which clinical practice guidelines for depression? An overview for busy practitioners. Br J Gen Prac 50 (2000) 908-911
15. Knaudt P.R., Connor K.M., Weisler R.H., et al. Alternative therapy use by psychiatric outpatients. J Nerv Ment Dis 187 (1999) 692-695
16. Kendler K.S., Davis C.G., and Kessler R.C. The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. Br J Psychiatry 170 (1997) 541-548
17. Nemeroff C.B., and Vale W.W. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 66 (2005) 5-13
18. Milak M.S., Parsey R.V., Keilp J., et al. Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch Gen Psychiatry 62 (2005) 397-408
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition: primary care version (1995), American Psychiatric Association, Washington, DC
20. US Preventative Services Task Force. Screening for depression: recommendations and rationale. Ann Intern Med 136 10 (2002) 760-764
21. Williams J.W., Noel P.H., Cordes J.A., et al. Is this patient clinically depressed?. JAMA 287 (2002) 1160-1170
22. Arroll B., Khin N., and Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ 327 (2003) 1144-1146
23. Whooley M.A., Avins A.L., Miranda J., et al. Case-finding instruments for depression. J Gen Intern Med 12 (1997) 439-445
24. Gilbody S., House A.O., and Sheldon T.A. Screening and case finding instruments for depression. Cochrane Database Syst Rev 4 (2005) CD002792
25. Williams J.W., Mulrow C.D., Chiquette E., et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 132 (2000) 743-756
26. Anderson I.M., and Tomenson B.M. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 310 (1995) 1433-1438
27. MacGillivray S., Arroll B., Hatcher S., et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 326 (2003) 1014-1026
28. Geddes J.R., Freemantle N., Mason J., et al. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev 2 (2000) CD001851
29. Treatment of depression-newer pharmacotherapies. Summary, evidence report/technology assessment. Agency for Health Care Policy and Research, Rockville, MD. Available at: http://www.ahrq.gov/clinic/deprsumm.htm. Accessed November 9, 2006.
30. Hansen R.A., Gartlehner G., Lohr K.N., et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143 (2005) 415-426
31. Kroenke K., West S.L., Swindle R., et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. A randomized trial. JAMA 286 (2001) 2947-2955
32. Straton J., and Cronholm P. Are paroxetine, fluoxetine, and sertraline equally effective for depression?. J Fam Pract 51 (2002) 285-286
33. Nieuwstraten C.E., and Dolovich L.R. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother 35 (2001) 1608-1613
34. Gregorian R.S., Golden K.A., Bahce A., et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother 36 (2002) 1577-1589
35. Thase M.E., Haight B.R., Richard N., et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66 (2005) 974-981
36. Modell J.G., Katholl C.R., Modell J.D., et al. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 61 (1997) 476-487
37. Zimmerman M., Posternak M.A., Attiullah N., et al. Why isn't bupropion the most frequently prescribed antidepressant?. J Clin Psychiatry 66 (2005) 603-610
38. Nurnberg H.G., Hensley P.L., Gelenberg A.J., et al. Treatment of antidepressant-associated sexual dysfunction with sildenafil. A randomized controlled trial. JAMA 289 (2003) 56-64
39. Fergusson D., Doucette S., Glass K.C., et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomized controlled trials. BMJ 330 (2005) 396-399
40. Gunnell D., Saperia J., and Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomized controlled trials submitted to the MHRA's safety review. BMJ 330 (2005) 385-391
41. Khan A., Khan S., Kolts R., et al. Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: analysis of FDA reports. Am J Psychiatry 160 (2003) 790-792
42. Martinez C., Rietbrock S., Wise L., et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 330 (2005) 389-393
43. Simon G.E., VonKorff M., Heiligenstein J.H., et al. Initial antidepressant of choice in primary care. JAMA 275 (1996) 1897-1902
44. Simon G.E., Heiligenstein J., Revicki D., et al. Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial. Arch Fam Med 8 (1999) 319-325
45. Burke W.J. Selective versus multi-transmitter antidepressants: are two mechanisms better than one?. J Clin Psychiatry 4 (2004) 37-45
46. Smith D., Dempster C., Glanville J., et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180 (2002) 396-404
47. Mann J.J. The medical management of depression. N Engl J Med 353 (2005) 1819-1833
48. Ellis P.M., and Smith D.A. Treating depression: the beyondblue guidelines for treating depression in primary care. "Not so much what you do but that you keep doing it.". Med J Aust 20 (2002) 77-83
49. Institute for Clinical Systems Improvement. Major depression in adults for mental health care (2004), Institute for Clinical Systems Improvement, Bloomington (MN)
50. Thase M.E., Rush A.J., Howland R.H., et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 59 (2002) 233-239
51. Lam R.W., Wan D.D., Cohen N.L., et al. Combining antidepressants for treatment-resistant depression. J Clin Psychiatry 63 (2002) 685-693
52. DeBattista C., and Lembke A. Update on augmentation of antidepressant response in resistant depression. Curr Psychiatry Rep 7 (2005) 435-440
53. Bschor T., Lewitska U., Sasse J., et al. Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry 36 (2003) 230-234
54. Barbosa L., Berk M., and Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 64 (2003) 403-407
55. Altshuler L.L., Bauer M., Frye M.A., et al. Does thyroid hormone supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 158 (2001) 1617-1622
56. Iosifescu D.V., Nierenberg A.A., Mischoulon D., et al. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry 66 (2005) 1038-1042
57. Smith W.T., Londburg P.D., Glaudin V., et al. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: A double-blind study. Am J Psychiatry 155 (1998) 1339-1345
58. Furukawa T.A., Streiner D.L., and Young L.T. Antidepressants and benzodiazepines for major depression. Cochrane Database Syst Rev 1 (2002) CD001026
59. Loonen A.J., Peer P.G., and Zwanikken G.J. Continuation and maintenance therapy with antidepressive agents. Meta-analysis of research. Pharm Weekbl Sci 13 (1991) 167-175
60. Geddes J.R., Carney S.M., Davies C., et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361 (2003) 653-661
61. Whittington C.J., Kendall T., Fonagy P., et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363 (2004) 1341-1345
62. Wagner K.D., Ambrosini P., Rynn M., et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder. Two randomized controlled trials. JAMA 290 (2003) 1033-1041
63. Garland E.J. Facing the evidence: antidepressant treatment in children and adolescents. CMAJ 170 (2004) 1-4
64. Khan A., Khan S.R., Walens G., et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 28 (2003) 552-557
65. Emslie G.J., Ryan N.D., and Wagner K.D. Major depression disorder in children and adolescents: clinical trial design and antidepressant efficacy. J Clin Psychiatry 66 (2005) 14-20
66. Hazell P., O'Connell D., Heathcote D., et al. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2 (2002) CD002317
67. Chambers C.D., Johnson K.A., Dick L.M., et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335 (1996) 1010-1015
68. Addis A., and Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 30 (2000) 89-94
69. Wisner K.L., Gelenberg A.J., Leonard H., et al. Pharmacologic treatment of depression during pregnancy. JAMA 282 (1999) 1264-1269
70. Einarson A., Fatoye B., Sarkar M., et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 158 (2001) 1728-1730
71. Chun-Fai-Chan B., Koren G., Fayez I., et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 192 (2005) 932-936
72. Huntington J., and Zantop V. Antidepressant medications in pregnancy. Am Fam Physician 70 (2004) 2195-2196
73. Koren G., Matsui D., Einarson A., et al. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?. CMAJ 172 (2005) 1457-1459
74. Kallen B. Noenate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 158 (2004) 312-316
75. Wulsin L.R., and Singal B.M. Do depressive symptoms increase the risk of for the onset of coronary disease? A systematic quantitative review. Psychosom Med 65 (2003) 201-210
76. Glassman A.H., O'Connor C.M., Califf R.M., et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288 (2002) 701-709
77. Roose S.P., Laghrissi-Thode F., Kennedy J.S., et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279 (1998) 287-291
78. Thase M.E., Tran P.V., Wiltse C., et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 25 (2005) 132-140
79. Dugan S.E., and Fuller M.A. Duloxetine: a dual reuptake inhibitor. Ann Phamacother 38 (2004) 2078-2085
80. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 65 (2004) 1642-1653
81. Wiart L., Petit H., Joseph P.A., et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 31 (2000) 1829-1832
82. Hackett M.L., Anderson C.S., and House A.O. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 36 (2005) 1098-1103
83. Bower P., Rowland N., Mellor Clark J., et al. Effectiveness and cost effectiveness of counseling in primary care. Cochrane Database Syst Rev 3 (2006) CD001025
84. Fava G.A., Rafanelli C., Grandi S., et al. Prevention of recurrent depression with cognitive behavioral therapy. Preliminary findings. Arch Gen Psychiatry 55 (1998) 816-820
85. Huibers M.J., Beurskens A.J., Bleijenberg G., et al. The effectiveness of psychosocial interventions delivered by general practitioners. Cochrane Database Syst Rev 2 (2003) CD003494
86. Blumenthal J.A., Babyak M.A., Moore K.A., et al. Effects of exercise training on older patients with major depression. Arch Intern Med 159 (1999) 2349-2356
87. Dunn A.L., Trivedi M.H., Kampert J.B., et al. Exercise treatment for depression. Efficacy and dose response. Am J Prev Med 28 (2005) 1-8
88. Linde K., and Mulrow C.D. St John's Wort for depression. Cochrane Database Syst Rev 2 (2005) CD000448
89. Schmidt P.J., Daly R.C., Bloch M., et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 62 (2005) 154-162
90. S-Adenosyl-l-methionine for treatment of depression, osteoarthritis, and liver disease. Summary, Evidence Report/Technology Assessment: Number 64. 2002. Rockville, Agency for Healthcare Research and Quality, Publication No. 02-E033.
91. Tuunainen A., Kripke D.F., and Endo T. Light therapy for non-seasonal depression. Cochrane Database Syst Rev 2 (2004) CD004050
92. Katon W., Russo J., von Korff M., et al. Long-term effects of a collaborative care intervention in persistently depressed primary care patients. J Gen Intern Med 17 (2002) 741-748
93. Neumeyer-Gromen A., Lampert T., Stark K., et al. Disease management programs for depression: a systematic review and meta-analysis of randomized controlled trials. Med Care 42 (2004) 1211-1221
94. Van der Wurff F.B., Stek M.L., Hoogendijk W.L., et al. Electroconvulsive therapy for the depressed elderly. Cochrane Database Syst Rev 2 (2003) CD003593
95. Martin J.L.R., Barbanoj M.J., Schlaepfer T.E., et al. Transcranial magnetic stimulation for treating depression. Cochrane Database Syst Rev 2 (2002) CD003493
96. Institute for Clinical Systems Improvement (ICSI). Major depression in adults in primary care (2004), Institute for Clinical Systems Improvement (ICSI), Bloomington (MN) p. 78